Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Completed · Phase 3 · NCT04799249
Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
At a glance
- Research payments reported, 2025
- $1,975
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 194
About the trial
- Sponsor
- G1 Therapeutics, Inc.
- Tested
- Trilaciclib (drug), Placebo (drug), Gemcitabine (drug), Carboplatin (drug)
- Dates
- Started 2021-05-14; completion 2024-05-24
- Results posted
- Not yet
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC.
From ClinicalTrials.gov, last updated 2024-08-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Pharmacosmos Therapeutics Inc. reported $1,975 in research payments for this study in 2025 (1 payments).
Products named: Trilaciclib
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,975
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.